Early cancer detection remains a vital pillar of proactive personal healthcare. When identified in its initial stages, cellular abnormalities and localised tumours can be managed far more effectively. In Singapore, alongside established physical and imaging screening procedures, blood tests have emerged as a supplementary option for early assessment. Knowing how these tests operate, their clinical performance, associated costs, and regulatory frameworks can help individuals make informed decisions in consultation with a doctor.
Contact UsBack To: Cancer Screening In Singapore
1. What Are Cancer Blood Tests And How Do They Work?
Cancer blood screening options in Singapore generally fall into two distinct diagnostic categories: Traditional Protein-Based Tumour Markers and Genomic Multi-Cancer Early Detection (MCED) Liquid Biopsies.
Traditional Tumour Marker Tests
Traditional tumour marker tests assess specific proteins in the bloodstream that may be elevated in the presence of certain cancers. Common examples include:
- PSA (Prostate-Specific Antigen): Associated with prostate health.
- AFP (Alpha-Fetoprotein): Associated with liver tissue evaluation.
- CEA (Carcinoembryonic Antigen): Associated with colorectal assessment.
- CA125: Associated with ovarian tissue evaluation.
Clinical Consideration
Tumour markers are primarily used to monitor known cancers or evaluate symptomatic patients under medical supervision. Health authorities generally do not recommend routine tumour marker screening for healthy, average-risk individuals because non-cancerous conditions can also raise protein levels, leading to potential false positives and unnecessary anxiety.
Multi-Cancer Early Detection (MCED) / Liquid Biopsies
MCED tests utilise genomic sequencing technology to analyse tiny fragments of circulating cell-free DNA (cfDNA) or circulating tumour DNA (ctDNA) shed into the bloodstream. By examining these genetic signals, MCED tests aim to detect multi-organ cancer indicators before physical symptoms manifest. These tests include SPOT-MAS, LucenceINSIGHT and Guardant Shield MCD.
Accuracy Metrics (Specificity vs. Sensitivity)
- Specificity (Low False-Positive Rate): Published validation studies report high specificity (approximately 99% to 99.8%). This means false positives are relatively uncommon, and most individuals without cancer receive a normal result.
- Sensitivity (Detection Capability): Sensitivity varies according to cancer type and stage. Because early-stage tumours shed significantly less DNA into the bloodstream, they are more challenging to detect than advanced-stage cancers. A negative or normal result does not completely rule out the presence of cancer.
- Comparing Test Options: Direct head-to-head comparisons between different commercial platforms (such as Spot-MAS, LucenceINSIGHT, or Guardant Shield MCD) cannot be made accurately, as their performance metrics originate from separate clinical trials involving differing patient populations.
2. Comparative Analysis Of Blood Screening Options
| Test Option | What It Analyses | Best Suited For | Key Clinical Considerations |
| Traditional Tumour Markers | Cancer-associated proteins in the blood | Monitoring diagnosed conditions or investigating specific clinical symptoms | Non-cancerous conditions can elevate protein levels; not recommended for routine healthy screening. |
| Spot-MAS | Circulating DNA signals across multiple organ systems | Individuals seeking an entry-level MCED screening option | Supplementary test; requires clinical evaluation and follow-up imaging if abnormal. |
| LucenceINSIGHT | Broad genomic DNA-based panel analysis | Individuals seeking a broader genomic assessment after doctor consultation | Abnormal findings require secondary diagnostic imaging or tissue biopsy. |
| Guardant Shield MCD | DNA methylation and fragment patterns | Individuals seeking newer-generation MCED genomic technology | Supplementary test; requires secondary clinical investigation if an abnormal signal is detected. |
3. Cost of Cancer Blood Tests In Singapore
Cost is an important consideration when evaluating private screening options. Prices vary depending on the panel complexity, provider fees, and medical consultation inclusions.
| Screening Option | Typical Estimated Cost Range (SGD)* | Cost Drivers |
| Traditional Tumour Markers | S$30 – S$150 per individual marker (S$100 – S$300 within health screening packages) | Overall cost depends on specific individual markers selected or bundled package inclusions. |
| Spot-MAS | S$800 – S$1,000 | Serves as an entry-level multi-cancer liquid biopsy option. |
| LucenceINSIGHT | S$600 – S$2,500 | Pricing scales based on panel size and the number of targeted cancer types covered. |
| Guardant Shield MCD | Pricing varies by clinic | Public pricing in Singapore is available upon consultation with private healthcare providers. |
*Note: Figures are reference estimates. Package pricing, promotional bundles, and doctor consultation fees vary across private healthcare institutions.
4. Who Should Consider Or Avoid Blood-Based Screening?
Who May Consider MCED Screening
An MCED blood test may be considered if an individual:
- Desires additional supplementary screening beyond standard national programmes.
- Has personal risk factors or a family history of cancer, evaluated in consultation with a doctor.
- Understands that an abnormal signal is not a definitive diagnosis and will require secondary diagnostic confirmation.
Who Should Avoid MCED Screening
MCED blood tests are not indicated if an individual:
- Has Active Symptoms: Experiencing warning signs such as unexplained weight loss, persistent bleeding, or a new physical lump requires immediate direct diagnostic evaluation rather than screening.
- Seeks a Guaranteed Result: Blood tests cannot detect every single cancer type, nor do they replace primary screening modalities.
5. Selecting the Right Screening Approach
| Personal Goal | Appropriate Screening Path |
| Evidence-based, cost-effective screening | Participate in Singapore’s national screening programmes under Healthier SG Screening (e.g., FIT kits for colorectal, mammography for breast, HPV DNA for cervical). |
| Supplementary screening on a targeted budget | Complete national population screenings first, followed by a doctor consultation regarding entry-level MCED blood options. |
| Comprehensive private health assessment | Schedule a medical consultation to review broad genomic panels (such as LucenceINSIGHT) or targeted imaging based on individual risk factors. |
| Experiencing active physical symptoms | Seek immediate medical attention for direct diagnostic imaging and specialist clinical evaluation. |
6. What Happens If A Blood Test Signal Is Positive?
A positive or abnormal MCED test result is not a diagnosis of cancer. It indicates that an abnormal genetic signal was detected, which requires structured clinical follow-up to evaluate whether a tumour is present and identify its precise location.
Depending on a physician’s clinical assessment, recommended next steps may include:
- Diagnostic Imaging: Ultrasound, Computed Tomography (CT), or Magnetic Resonance Imaging (MRI).
- Endoscopic Procedures: Colonoscopy or Gastroscopy.
- Pathology Assessment: Tissue biopsy or confirmatory laboratory testing.
Note: Many abnormal screening signals are subsequently found to stem from non-cancerous causes.
Frequently Asked Questions
Can a cancer blood test replace a routine mammogram or colonoscopy?
No. Blood tests act as supplementary screening tools rather than direct replacements for primary screening methods such as mammography, cervical screening, or colonoscopies.
Are MCED blood tests covered by MediSave or Integrated Shield Plans?
Voluntary, supplementary MCED tests in asymptomatic individuals are currently paid out-of-pocket and are generally not claimable under MediSave or standard Integrated Shield Plans.
How long does it take to receive MCED blood test results in Singapore?
Turnaround time is typically 2 to 3 weeks, as samples undergo specialised genomic processing and bioinformatic analysis in accredited clinical laboratories.
Accessing Cancer Screening in Singapore
Because an abnormal result requires structured clinical management, blood-based screening should always be accessed through a registered healthcare facility capable of providing comprehensive medical consultation, diagnostic imaging referrals, and specialist follow-up care.
Preferred Medical Centre For Cancer Screening
[SG] Featured Doctor- Dr Kevin Koo
To discuss whether supplementary cancer blood testing is suitable for your individual health profile, schedule a consultation with a qualified medical practitioner.
Contact UsBack To: Cancer Screening In Singapore
All content on this site is informative only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment, and should never be relied upon for specific medical advice. If you are experiencing a medical emergency, call 995 immediately or go to the nearest Accident & Emergency department.
health365.sg is a member of Group 365Asia.